Role of Antiplatelet Therapy in Secondary Prevention of Acute Coronary Syndrome

被引：7

作者：

Pankert, Mathieu ^{[2
]}

Quilici, Jacques ^{[2
]}

Cuisset, Thomas ^{[1
,2
,3
]}

机构：

[1] CHU Timone, Hematol Lab, F-13385 Marseille, France

[2] CHU Timone, Dept Cardiol, F-13385 Marseille, France

[3] Fac Med Marseille, INSERM, U626, F-13385 Marseille, France

来源：

JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH | 2012年 / 5卷 / 01期

关键词：

Acute coronary syndrome; Aspirin; Coronary stenting; P2Y12; blockers; ACUTE MYOCARDIAL-INFARCTION; PROTON-PUMP INHIBITORS; POSTTREATMENT PLATELET REACTIVITY; CLOPIDOGREL-STATIN INTERACTION; CALCIUM-CHANNEL BLOCKERS; ASPIRIN RESISTANCE; CARDIOVASCULAR EVENTS; DOUBLE-BLIND; RECEPTOR ANTAGONIST; TREATMENT ADHERENCE;

D O I：

10.1007/s12265-011-9329-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiovascular disease is one of the major causes of death in developed countries, mainly related to coronary artery disease and its acute complications. Platelets play a great role in the pathogenesis of acute thrombotic events of coronary artery disease when silent chronic disease becomes acutely symptomatic. Platelet importance in coronary artery disease and pathophysiology of acute events support the large benefit of antiplatelet agents for both acute management of ACS and secondary prevention. Recent developments in oral antiplatelet therapy raised questions about the choice of the molecules, the use of single or double therapy, and the optimal dosing and duration of treatment. The present review aims to provide a current appraisal of antiplatelet therapy use after ACS and to summarize available scientific evidence for an optimal use of antiplatelet agents in daily practice, including the new P2Y12 blockers.

引用

页码：41 / 51

页数：11

共 89 条

[81] Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation [J].

Van de Werf, Frans ;

Bax, Jeroen ;

Betriu, Amadeo ;

Blomstrom-Lundqvist, Carina ;

Crea, Filippo ;

Falk, Volkmar ;

Filippatos, Gerasimos ;

Fox, Keith ;

Huber, Kurt ;

Kastrati, Adnan ;

Rosengren, Annika ;

Steg, P. Gabriel ;

Tubaro, Marco ;

Verheugt, Freek ;

Weidinger, Franz ;

Weis, Michael ;

Vahanian, Alec ;

Camm, John ;

De Caterina, Raffaele ;

Dean, Veronica ;

Dickstein, Kenneth ;

Filippatos, Gerasimos ;

Funck-Brentano, Christian ;

Hellemans, Irene ;

Kristensen, Steen Dalby ;

McGregor, Keith ;

Sechtem, Udo ;

Silber, Sigmund ;

Tendera, Michal ;

Widimsky, Petr ;

Zamorano, Jose Luis ;

Silber, Sigmund ;

Aguirre, Frank V. ;

Al-Attar, Nawwar ;

Alegria, Eduardo ;

Andreotti, Felicita ;

Benzer, Werner ;

Breithardt, Ole ;

Danchin, Nicholas ;

Mario, Carlo Di ;

Dudek, Dariusz ;

Gulba, Dietrich ;

Halvorsen, Sigrun ;

Kaufmann, Philipp ;

Kornowski, Ran ;

Lip, Gregory Y. H. ;

Rutten, Frans .

EUROPEAN HEART JOURNAL, 2008, 29 (23) :2909-2945

[82]

WALLENTIN L, 1990, LANCET, V336, P827

[83] Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease [J].

Wallentin, Lars ;

Varenhorst, Christoph ;

James, Stefan ;

Erlinge, David ;

Braun, Oscar Oe ;

Jakubowski, Joseph A. ;

Sugidachi, Atsuhiro ;

Winters, Kenneth J. ;

Siegbahn, Agneta .

EUROPEAN HEART JOURNAL, 2008, 29 (01) :21-30

[84] Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes [J].

Wallentin, Lars ;

Becker, Richard C. ;

Budaj, Andrzej ;

Cannon, Christopher P. ;

Emanuelsson, Hakan ;

Held, Claes ;

Horrow, Jay ;

Husted, Steen ;

James, Stefan ;

Katus, Hugo ;

Mahaffey, Kenneth W. ;

Scirica, Benjamin M. ;

Skene, Allan ;

Steg, Philippe Gabriel ;

Storey, Robert F. ;

Harrington, Robert A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (11) :1045-1057

[85] Randomized comparison of Prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention -: Results of the joint utilization of medications to block platelets optimally (JUMBO)-TIMI 26 trial [J].

Wiviott, SD ;

Antman, EM ;

Winters, KJ ;

Weerakkody, G ;

Murphy, SA ;

Behounek, BD ;

Carney, RJ ;

Lazzam, C ;

McKay, RG ;

McCabe, CH ;

Braunwald, E .

CIRCULATION, 2005, 111 (25) :3366-3373

[86] Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 [J].

Wiviott, Stephen D. ;

Braunwald, Eugene ;

Angiolillo, Dominick J. ;

Meisel, Simha ;

Dalby, Anthony J. ;

Verheugt, Freek W. A. ;

Goodman, Shaun G. ;

Corbalan, Ramon ;

Purdy, Drew A. ;

Murphy, Sabina A. ;

McCabe, Carolyn H. ;

Antman, Elliott M. .

CIRCULATION, 2008, 118 (16) :1626-1636

[87] Prasugrel versus clopidogrel in patients with acute coronary syndromes [J].

Wiviott, Stephen D. ;

Braunwald, Eugene ;

McCabe, Carolyn H. ;

Montalescot, Gilles ;

Ruzyllo, Witold ;

Gottlieb, Shmuel ;

Neumann, Franz-Joseph ;

Ardissino, Diego ;

De Servi, Stefano ;

Murphy, Sabina A. ;

Riesmeyer, Jeffrey ;

Weerakkody, Govinda ;

Gibson, C. Michael ;

Antman, Elliott M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (20) :2001-2015

[88] Early and late effects of clopidogrel in patients with acute coronary syndromes [J].

Yusuf, S ;

Mehta, SR ;

Zhao, F ;

Gersh, BJ ;

Commerford, PJ ;

Blumenthal, M ;

Budaj, A ;

Wittlinger, T ;

Fox, KAA .

CIRCULATION, 2003, 107 (07) :966-972

[89]

Yusuf S, 2001, NEW ENGL J MED, V345, P494

← 1 2 3 4 5 6 7 8 9 →